CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-241

One of many examples highlighting how undervalued this stock is. We have here the fastest growing MIGS company with several recent bullish announcements which will help drive performance well into the future, yet the lowest ev/sales multiple of all MIGS companies (and also very low relative to other healthcare companies more broadly). Not to mention this company is arguably the closest of the bunch to being profitable (which is remarkable considering how fast it's growing). As I said the other day, and incredibly easy stock to sit on given all the info/data we have and the very low valuation relative to all that information.